Confronting Inequities in STI Prevention, Diagnostics and Care

Session 3 – Management Guidelines

What’s the evidence and what’s new? WHO Guidelines on the Management of Symptomatic STIs in resource-constrained settings

Sunday September 4th 2022, 14:30 – 16:00
Venue: Gwayi Conference Room

Although the STI syndromic approach has some shortcomings, it remains an essential component of managing people with symptoms of STIs. WHO Guidelines for the Management of symptomatic STIs aim to raise the quality of managing symptomatic STIs by providing evidence-informed recommendations. In addition, given the increasing availability of molecular assays and development of low-cost point-of-care tests for STIs, these guidelines also provide recommendations on the use of these tests in settings in which they are accessible. These guidelines are intended to support countries in updating their national guidance for the management of people with symptoms of STIs and in guiding the health-care providers at the frontline – at the primary health-care level, secondary health-care level and at the tertiary health-care delivery point to ensure the delivery of adequate, acceptable and equitable STI care for all populations in need of STI services.

The objectives of this session are to:

  1. Discuss the evidence and recommendations of the new WHO guidelines to manage symptomatic STIs.
  2. Highlight the implementation and operational considerations in rolling out these guidelines in countries./

Chairs: Teodora Wi (Lead, Global STIs programmes, WHO Switzerland) and Francis Ndowa (Director, Skin & GU Medicine Clinic, Harare, Zimbabwe; 23rd IUSTI 2022 Congress President, Zimbabwe)

14:30-15:00 Overview of the WHO STI guidelines for symptomatic STIs Teodora Wi (WHO, Switzerland)
15:00-15:10 Genital Ulcer Disease Management David Lewis (Western Sydney Sexual Health Center, and University of Sydney, Australia)
15:10-15:25 Implementation Considerations Philippe Mayaud (London School of Hygiene and Tropical Medicine, UK)
15:25-15:40 Laboratory Considerations Magnus Unemo (Orebro University, Sweden and WHO Collaborating Centre for STIs)
15:40-15:50 Perspectives from Health Care Provider Anna Machiha (National STI Programme, Zimbabwe)
Van Thi Thuy Nquyen ( WHO, Vietnam)
15:50-16:00 Questions and discussion